ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
International Stem Cell CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28+0.00 (+0.89%)
Close on Oct 19, 2026
- Market cap
- $2.27M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
55.7%−5.3 pts over 5 years
Operating margin
-2.9%+36.6 pts over 5 years
Net margin
-4.6%+33.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.2% | +3.6% | +5.0% | +1.9% | |
| Gross profit | -4.8% | +1.0% | +3.1% | -0.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -42.8% | 75.4% | 10.5% | |
| Return on assets | -15.2% | -45.8% | -8.4% | |
| Current ratio | 0.69 | 1.47 | 0.74 | |
| Interest coverage | -808.5× | -24.9× | -1.8× | |
| Inventory turnover | 1.4× | 2.6× | 3.0× | |
| Capex to revenue | 3.2% | 0.4% | 0.5% | |
| Diluted shares | 3M | 8M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
International Stem Cell generated $2.58M from operations and spent $313.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.58M
Used
$313.00K
Capital expenditure$313.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.6%
×Asset turnover1.82×
×Equity multiplier-1.25×
=Return on equity, FY202510.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.6% | 1.82× | -1.25× | 10.5% |
| FY2024 | -2.3% | 1.72× | -1.30× | 5.1% |
| FY2023 | -1.7% | 1.48× | -1.21× | 3.0% |
| FY2022 | -4.0% | 1.62× | -1.11× | 7.3% |
| FY2021 | -12.5% | 1.40× | -1.15× | 20.2% |
| FY2020 | -38.2% | 1.20× | -1.65× | 75.4% |
| FY2019 | -45.0% | 1.31× | -41.07× | 2430.2% |
| FY2018 | -19.2% | 1.51× | 3.19× | -92.6% |
| FY2017 | -81.4% | 1.07× | 2.53× | -220.4% |
| FY2016 | -15.1% | 1.01× | 2.82× | -42.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$418.00K
- Cash generatingOperating cash flow above zero$8.00K
- Return on assets improvedROA up on the prior year-3.9% → -8.1%
- Earnings backed by cashOperating cash flow above net income$8.00K vs -$418.00K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.76 → 0.74
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year58.57% → 55.68%
- More efficientAsset turnover rose1.69 → 1.76